STAAR Surgical (STAA) Stock Could Be Cheap As Shares Fell 82%

STAAR Surgical has seen its share price slide over several years, even as management highlights new hires and product expansion plans. That split between a weaker stock chart and an active business story raises a straightforward question for you as an investor: Is the current valuation supported by the cash the company is expected to generate?

• Over the past 5 years, STAAR Surgical’s share price has fallen 81.6%, which puts the focus squarely on whether the current market value still lines up with what its cash flows may justify.
• The recent appointment of Andrew Pilon to lead business development, alongside reported revenue growth and product expansion efforts, can influence how quickly STAAR Surgical converts its ophthalmic opportunity into sustainable cash generation.
• If you'd rather focus on sales, this one's for you. See why STAAR Surgical's 3.2x P/S tells a different valuation story.

The stock’s next move may depend on whether STAAR Surgical’s present share price is in line with its intrinsic value estimate based on its cash flows.

If you are weighing whether STAAR Surgical’s share price decline and cash flow outlook still fit your portfolio, it can help to compare this setup with 29 high quality undervalued stocks.

Does STAAR Surgical Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) model here focuses on the cash STAAR Surgical could return to shareholders over time. Latest twelve month free cash flow is reported as a loss of $19.10 million, yet the forecast path assumes that future free cash flow turns positive and then continues growing in later years. That shift from cash burn to surplus is a key reason the intrinsic value estimate comes out meaningfully above the current share price of $21.67.

Analyst sourced projections feed into the early stage of the model, with later years based on gradually moderating growth assumptions rather than extreme hockey stick curves. Despite the Q2 revenue surge and earnings surprise in 2026, the stock price reaction has stayed muted, which helps explain why the DCF output sits above where the market is pricing STAAR Surgical today. To see how large that gap is, and how sensitive it is to different growth or discount rate inputs, you can review the full cash flow model and its intrinsic value estimate in. Find out what STAAR Surgical could be worth using our Discounted Cash Flow (DCF) estimate.

The STAAR Surgical Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the STAAR Surgical valuation puzzle leaves off and spell out which assumptions about future growth, margins and earnings would need to hold for the stock to be worth materially more or less than today. They live on Simply Wall St's Community page. Each scenario links a specific fair value to a clear set of potential catalysts and risks so you can see over time which version of STAAR Surgical's story is gaining traction.

Community views on STAAR Surgical are split between those who see operating discipline creating potential upside and those who focus on concentration and governance risk.

Bull case: 23% undervalued

"The main thing that has to go right is that STAAR Surgical converts its strong position in China and rising ex-China EVO and EVO+ adoption into durable market share gains…"

Discover why this Narrative puts STAAR Surgical at 23% undervalued.

Bear case: 14% overvalued

"Bearish analysts expect STAAR Surgical to remain heavily exposed to a single refractive lens franchise, and any disruption to EVO or EVO Plus adoption could potentially pressure growth and profitability for an extended period…"

Explore why this Narrative puts STAAR Surgical at 14% overvalued.

One more STAAR Surgical check before you rely on the price tag

Before you lean too heavily on where STAAR Surgical trades against its cash flow estimate, it helps to see which risk checks our research has flagged and decide how much they matter to you. Take a closer look at 1 warning sign before settling on a valuation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com